GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into agreements with experienced and accomplished distributors in Germany, Austria, Switzerland, and key Nordic markets..

康涅狄格州吉尔福德——（商业新闻短讯）——Hyperfine（纳斯达克：HYPR）是一家开创性的健康技术公司，它通过首个FDA批准的便携式磁共振（MR）脑成像系统重新定义了脑成像。Swoop®系统今天宣布，它已与德国、奥地利、瑞士和主要北欧市场经验丰富且成就斐然的分销商达成协议。。

With the Swoop® system’s transformative, affordable, and accessible platform, Hyperfine aims to serve more clinicians and patients needing brain imaging across the globe. Plans to introduce the system into international markets represent a significant step in the company’s commercial growth. With the recent addition of distributors covering Germany, Austria, Switzerland, and the major Nordic markets, along with previously appointed distributors in France, the United Kingdom, and Italy, Hyperfine is now positioned for commercial expansion into twelve European countries..

凭借Swoop®系统的变革性、经济实惠且可访问的平台，Hyperfine旨在为全球更多需要脑部成像的临床医生和患者提供服务。将该系统引入国际市场的计划是该公司商业增长的重要一步。随着最近增加了覆盖德国、奥地利、瑞士和主要北欧市场的分销商，以及之前在法国、英国和意大利指定的分销商，Hyperfine现在已定位于向十二个欧洲国家进行商业扩张。。

'We are thrilled with the initial feedback from clinicians in European sites. The positive feedback highlights the Swoop® system's potential to significantly impact adult and pediatric care throughout Europe,' said Maria Sainz, President and CEO of Hyperfine.

“我们对欧洲网站临床医生的初步反馈感到兴奋。Hyperfine总裁兼首席执行官玛丽亚·赛恩斯（MariaSainz）说，积极的反馈突显了Swoop®系统对整个欧洲成人和儿科护理产生重大影响的潜力。

The system being introduced to the European markets is commercialized in the U.S. and represents the highest-performing Swoop® system to date in terms of image quality, speed, and usability. The company’s strong track record of securing international approvals enables its expansion into global markets..

引入欧洲市场的系统在美国已商业化，在图像质量、速度和可用性方面代表了迄今为止性能最高的Swoop®系统。该公司在获得国际批准方面的良好记录使其能够扩展到全球市场。。

In addition to the company’s European expansion plans, Hyperfine announced in May 2024 a distribution agreement to develop Asian markets, including India.

除了该公司的欧洲扩张计划外，Hyperfine于2024年5月宣布了一项分销协议，以开发包括印度在内的亚洲市场。

For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.

有关Swoop®便携式MR Imaging®系统的更多信息，请访问hyperfine.io。

About the Swoop® Portable MR Imaging® System

关于Swoop®便携式MR成像®系统

The Swoop® Portable MR Imaging® system is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical.

Swoop®便携式MR成像®系统已获得美国食品和药物管理局（FDA）的批准，可用于所有年龄段患者的脑部成像。它是一种便携式超低场磁共振成像设备，用于产生显示头部内部结构的图像，而全面的诊断检查在临床上并不实用。

When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system also has CE certification in the European Union and UKCA certification in the United Kingdom. The Swoop® system is commercially available in a select number of international markets..

当由训练有素的医生解释时，这些图像提供的信息可用于确定诊断。Swoop®系统还拥有欧盟CE认证和英国UKCA认证。Swoop®系统可在多个国际市场上买到。。

About Hyperfine, Inc.

关于Hyperfine，Inc。

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The mission of Hyperfine, Inc.

Hyperfine，Inc.（纳斯达克股票代码：HYPR）是一家开创性的健康技术公司，它使用Swoop®系统重新定义了大脑成像，Swoop®系统是首款FDA批准的便携式超低场磁共振脑成像系统，能够在多个护理点提供成像。Hyperfine公司的使命。

is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care.

是通过变革性的，可访问的，临床相关的诊断成像在全球范围内彻底改变患者护理。乔纳森·罗斯伯格（JonathanRothberg）博士在一个名为4Catalyzer的科技孵化器中创立了Hyperfine公司。科学家、工程师和物理学家出于对重新定义大脑成像方法以及临床医生如何将可访问的诊断成像应用于患者护理的热情，开发了Swoop®系统。

For more information, visit hyperfine.io..

有关更多信息，请访问hyperfine.io。。

The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

Hyperfine徽标、Swoop和便携式MR成像是Hyperfine，Inc.的注册商标。

Forward-Looking Statements

前瞻性声明

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events.

本新闻稿包括1995年《私人证券诉讼改革法案》中“安全港”条款所指的“前瞻性声明”。Hyperfine，Inc.（以下简称“公司”）的实际业绩可能与其预期、估计和预测不同，因此，您不应将这些前瞻性陈述视为对未来事件的预测。

Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements.

诸如“预期”、“估计”、“项目”、“预算”、“预测”、“预期”、“打算”、“计划”、“可能”、“会”、“可能”、“应该”、“相信”、“预测”、“潜在”、“继续”等词语以及类似表达（或此类词语或表达的负面版本）旨在识别此类前瞻性陈述。

These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

这些前瞻性陈述包括但不限于公司的目标和商业计划，公司产品和服务的益处，公司未来的业绩及其实施战略的能力。这些前瞻性陈述涉及重大风险和不确定性，可能导致实际结果与预期结果产生重大差异。

Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the .

这些因素大多不在公司控制范围内，难以预测。可能导致这种差异的因素包括但不限于：公司产品开发和商业化活动的成功、成本和时间安排，包括Swoop®系统被医疗保健专业人员接受和使用的程度；新型冠状病毒肺炎对公司业务的影响；无法维持公司A类普通股在纳斯达克的上市；公司无法盈利增长和管理增长，无法留住关键员工；适用法律法规的变更；公司未来无法筹集资金；的。